Evogene Ltd. (EVGN)
NASDAQ (CM) NASDAQ (CM) Primary 
TASE Summary
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript
Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Evogene Ltd. (EVGN) Q4 2025 Earnings Call Transcript
Evogene Ltd. (EVGN) Q3 2025 Earnings Call Transcript
Evogene Ltd. ( EVGN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Ofer Haviv - CEO, President & Director Yaron Eldad - Chief Financial Officer Presentation Operator Welcome to Evogene's Third Quarter 2025 Results Conference Call.
Evogene Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 456,587 | $351,571.99 | $214,595.89 | -$136,976.1 | -38.96% |
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 500 | $1,535 | $235.5 | -$1,299.5 | -84.66% |
Evogene Ltd. (EVGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Evogene Ltd. ever had a stock split?
Evogene Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ofer Haviv CEO | NASDAQ (CM) Exchange | M4119S104 CUSIP |
| IL Country | 52 Employees | - Last Dividend | 25 Jul 2024 Last Split | - IPO Date |
Overview
Evogene Ltd. is a computational biology company that leverages its unique Computational Predictive Biology (CPB) platform to discover and develop innovative products across life-science based industries, including human health and agriculture. The company pursues advancements in agriculture to enhance plant performance, human health through the development of microbiome-based therapeutics, and industrial applications by producing improved agricultural feedstock. Founded in 1999, and based in Rehovot, Israel, Evogene operates globally, with activities in the United States, Brazil, and other international locations. It maintains strategic partnerships and licensing agreements with key players in the agricultural sector, such as BASF SE, Corteva, and Bayer, highlighting its collaborative approach to innovation and product development.
Products and Services
- Agriculture:
- Human Health:
- Industrial Applications:
- Medical Cannabis:
Evogene's agriculture segment focuses on developing seed traits, ag-chemical products, and ag-biological products designed to optimize plant performance. This includes innovations for major crops like corn, soybean, wheat, rice, and cotton, aiming to increase yield, resist pests and diseases, and enhance drought tolerance.
In the human health segment, Evogene discovers and develops microbiome-based therapeutics targeting critical health issues such as immuno-oncology treatments, gastrointestinal (GI) related disorders, and combating antimicrobial resistance organisms. This approach represents a novel and promising field of therapeutic development leveraging the human microbiome.
Evogene’s industrial applications segment is dedicated to developing enhanced castor bean seeds, providing a superior feedstock source for bio-based industrial uses. This work supports the production of materials that are sustainable and renewable, aligning with global trends towards greener industrial processes.
The company extends its biotechnological expertise to the development of medical cannabis products. By applying its CPB platform, Evogene aims to introduce innovation within the cannabis industry, focusing on the production of products with improved traits and consistency.
